AstraZeneca's profit rises 20% to $2,031 million until March
The pharmaceutical company AstraZeneca totalled 2.180 million dollars (around 2.031 million euros) profit in the first quarter, 20% more than in the same period last year.
© Shutterstock
Economia AstraZeneca
In a statement, the company revealed that pre-tax profit totalled 2.8 billion dollars (2.618 billion euros) between January and March, a 23.7% year-on-year increase.
In turn, operating profit rose 22% in the first three months of the year, reaching 3,115 (2.912 billion euros).
Up to March, the total value of revenue stood at 12.679 billion dollars (11.853 billion euros), up 19% compared to the first quarter of 2023, a trend justified by the increase in sales, particularly in the oncology sector.
Quoted in the same note, AstraZeneca's CEO, Pascal Soriot, stated that the beginning of the year "was very strong" for the company, with a "substantial growth" in revenue.
"This year we announced positive results in the Imfinzi and Tagrisso trials [for lung cancer]. We also expect to have results from other important trials throughout the year," he pointed out.
At the last general meeting, the company announced a 7% increase in its annual dividend.
Read also: AstraZeneca manufacturer makes Shanghai its fifth strategic centre (Portuguese version)
Descarregue a nossa App gratuita.
Oitavo ano consecutivo Escolha do Consumidor para Imprensa Online e eleito o produto do ano 2024.
* Estudo da e Netsonda, nov. e dez. 2023 produtodoano- pt.com